Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 4, 2024
Reporting Period: Event date October 4, 2024; Signed October 9, 2024.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a corporate governance action regarding equity compensation.
Material Changes
The Board of Directors amended the Company's 2019 Inducement Stock Incentive Plan. The aggregate number of shares issuable under the plan was increased from 4,804,000 to 6,054,000 shares of common stock.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document serves solely to disclose the amendment to the stock incentive plan.
Investor Verification Checklist
- Verify the total number of shares authorized under the amended 2019 Inducement Stock Incentive Plan (6,054,000).
- Review the full text of Amendment No. 4 to the 2019 Inducement Stock Incentive Plan (Exhibit 99.1) for specific terms and conditions.
- Assess the potential dilution impact of the increased share pool on existing shareholders.